<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Hua Medicine — News on 6ix</title>
    <link>https://6ix.com/company/hua-medicine</link>
    <description>Latest news and press releases for Hua Medicine on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 03 Mar 2026 05:48:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/hua-medicine" rel="self" type="application/rss+xml" />
    <item>
      <title>Hua Medicine Announces the Approval of Dorzagliatin for Marketing in Hong Kong SAR, China</title>
      <link>https://6ix.com/company/hua-medicine/news/hua-medicine-announces-the-approval-of-dorzagliatin-for-marketing-in-hong-kong-sar-china</link>
      <guid isPermaLink="true">https://6ix.com/company/hua-medicine/news/hua-medicine-announces-the-approval-of-dorzagliatin-for-marketing-in-hong-kong-sar-china</guid>
      <pubDate>Tue, 03 Mar 2026 05:48:00 GMT</pubDate>
      <description>Hua Medicine (&quot;the Company&quot;, Hong Kong Stock Exchange Stock Code: 2552.HK) announced today that its global first-in-class glucokinase activator (GKA) dorzagliatin (Trade name: MYHOMSIS®, 華領片®) has been approved for marketing by the Pharmaceutical Service of the Department of Health of the Hong Kong Special Administrative Region of China for the treatment of Type 2 diabetes in adults.</description>
    </item>
    <item>
      <title>Hua Medicine Announces 2025 Interim Results</title>
      <link>https://6ix.com/company/hua-medicine/news/hua-medicine-announces-2025-interim-results</link>
      <guid isPermaLink="true">https://6ix.com/company/hua-medicine/news/hua-medicine-announces-2025-interim-results</guid>
      <pubDate>Thu, 28 Aug 2025 09:58:00 GMT</pubDate>
      <description>Hua Medicine (the &quot;Company&quot;, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the &quot;Reporting Period&quot;), as well as the Company&apos;s business progress during the first half of the year and future outlook. During the Reporting Period, the commercialization of the Company&apos;s core product, HuaTangNing (华堂宁®) (dorzagliatin tablets), accelerated. The Company&apos;s independent operational capabilities improved significantly. R&amp;D</description>
    </item>
  </channel>
</rss>